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Inhaled heparin is effective in exacerbations
of asthma
K. E. BENDSTRUP AND J. I. JENSEN
Department of Medicine, Esbjerg Hospital, DenmarkIntroduction
Despite advances in anti-asthmatic therapy, new antiasth-
matic agents are still needed. Inhaled heparin may be such
an agent due to its often over-looked anti-inflammatory
properties. We have previously characterized heparin
aerosols and determined the dose administered to the lower
respiratory tract by inhalation in normal subjects (1,2). We
used this knowledge in two patients who did not respond to
systemic corticosteroids during exacerbations. This is the
report of the outcome.
Patient 1
Patient 1 is a 57-year old female who had had progressive,
allergic asthma for 6 years. Inhaled steroids and long-acting
b2-agonists had maintained spirometry at normal levels:
forced expiratory volume in 1 sec (FEV1) 300 1 (pred.
310), forced vital capacity (FVC) 380 1 (400). Over 6
months her clinical condition had deteriorated despite
courses of systemic steroid (prednisolone, 30 mg for 1 week
tapered by 5 mg every third day) and ampicillin (750 mg
t.i.d. for 10 days) as sputum cultures yielded monocultures
of H. Influenzae twice.
On the 16th day of another steroid course, at 15 mg daily,
she was admitted due to increased dyspnoea and no regular
sleep for several nights. FEV1 was 153 l and FVC 230 1.
Chest X-ray and a ventilation–perfusion ratio (V/Q) scan
were normal, leucocytes were 112 (pred 29–1046109 l71),
and H. Influenzae sensitive to ampicillin was again cultured
from sputum. Prednisolone was increased to 30 mg and
another course of ampicillin begun. As no improvement
had occured after days, the patient agreed to try inhaled
heparin.
One hundred thousand IU of unfractionated sodium
heparin (Leo Pharmaceutical Ltd.) was nebulized in a
Sidestream jet nebulizer (Medic-Aid, Bognor Regis, Eng-
land) at a flow rate of 10 l min71; thereby 7000 IU of
heparin was administered to the lower respiratory tract
daily for 5 days (2). Spirometry and symptoms improved
immediately; on the third day FEV1 was 2551, FVC 355 1Received 8 June 1999 and accepted 26 August 1999
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0954-6111/00/020174+02 $35?00/0and sleep was uninterrupted. The patient was discharged on
the 5th day, with steroids tapered as usual. Inhaled heparin
was administered once weekly for 3 weeks; on the first visit
there were no symptoms and spirometry had normalized
(FEV1 308 1, FVC 392 1) and remained so beyond the
discontinuation of steroids (4 weeks). Daily/weekly counts
of platelets, activated partial thromboplastin time and
prothrombin time remained normal.
Patient 2
Patient 2 is a 67-year old female with allergic asthma since
childhood. Her asthma had remained well-controlled on
inhaled steroids and long-acting b2-agonists. Her optimal
spirometry was FEV1 153 1 (pred. 196 1), and FVC 200
(pred. 206 1).
Four weeks prior to admission, an exacerbation was
treated in another hospital ward with prednisolone 30 mg
for 14 days, with increase up to 50 mg daily for 3 days
without eect. The patient was readmitted due to further
deterioration with diculties performing activities of daily
living and diculty sleeping. Spirometry on admission was:
FEV1 098 1 and FVC 140 1. Chest X-ray and V/Q scans
were normal. Leucocytes were 946109 l71, and there were
neither fever nor sputum. The usual inhaled medication was
maintained. Conjunctivitis and rhinitis appeared on the 5th
day of admission. The patient was reluctant to accept
another course of systemic steroids and instead agreed to
try inhaled heparin. Heparin administration and dosage
was similar to that of patient 1. Symptoms improved
immediately, the conjunctivitis and rhinitis disappearing
within the hour after the first inhalation, and sleep was only
interrupted once the following night. Spirometry improved
significantly to a maximum FEV1 of 124 1 and FVC of
184 1 after 5 days when she was discharged free of
symptoms. One week after discharge, FEV1 had improved
to 130 1, and FVC to 193 1, remaining unchanged for the
following 4 weeks. The eosinophil count remained elevated
(1840–16506109 l71), while platelets, APTT and pro-
thrombin time remained unchanged.
Discussion
The lower respiratory tract dose delivered to normal
subjects by nebulization of 100 000 IU in the Sidestream# 2000 HARCOURT PUBLISHERS LTD
INHALED HEPARIN AND ASTHMA 175jet nebulizer is 7000 IU, but may be somewhat larger in
asthmatic subjects (3). We have studied single lower
respiratory tract doses of up to 28 000 IU
(nebulizer charge 400 000 IU) and found very small and
clinically irrelevant changes in coagulation variables, but
the eects of repeated daily doses are unknown; in these
two patients no untoward eects were observed during 5
days.
Heparin inhibits mast cell activation and mast cell
mediators, possibly through inhibition of 1,4,5-tripho-
sphate receptors (4). Heparin also inhibits eosinophil cell
migration and eosinophil cationic proteins (5). Such eects
may be the mechanism behind the attenuation of exercise-,
histamine- and allergen-induced bronchoconstriction (6,7).
Not only may the eects of inhaled heparin in asthma
dier from those of steroids, but the side eects are highly
likely to be fewer and milder than those needed for anti-
coagulation and thrombotic therapy. Therefore, when the
lower respiratory tract doses and their distribution in
asthmatic subjects and the eects of repeated dosing of
aerosolized heparin have been determined, clinical trials of
heparin against steroids and leukotriene antagonists are
desirable in order to determine the potential place of
aerosolized heparin in the treatment of asthma.References
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